Aurora Cannabis Gears Up for IPO

Print Email

Aurora Cannabis has filed a 40-F form with the U.S. Securities and Exchange Commission (SEC) in preparation for its initial public offering (IPO). No pricing details were given. The company intends to list its shares on the New York Stock Exchange under the symbol ACB.

This company is one of the world’s largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.

Highly differentiated from its peers, Aurora has established a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities that integrate leading-edge technologies across all processes, defined by extensive automation and customization, resulting in the massive scale production of high-quality product at ultra-low costs.

Intended to be replicable and scalable globally, these production facilities are designed to produce cannabis of significant scale, with high-quality, industry-leading yields and ultra-low per gram production costs.

Terry Booth, CEO of Aurora, commented:

Through our NYSE listing, Aurora joins an established group of mature global brands with improved access and exposure to an engaged international institutional investor audience. Aurora’s high-paced execution has made it one of the world’s leading cannabis companies. We have grown from being a licensed producer with a single facility, to a horizontality differentiated and vertically integrated global organization with a funded production capacity in excess of 500,000 kg a year, sales and operations on five continents, and a team of more than 1,500 employees.

He added:

Our purpose-built, indoor grow facilities, designed to meet the stringent requirements for furnishing product to international markets, have made Aurora the largest supplier of medical cannabis in Europe. We are also well-prepared for the launch of the domestic adult consumer use market in Canada with a portfolio of strong consumer brands and coast-to-coast provincial supply arrangements covering 98% of the Canadian population. I am proud of our achievements to date, and look forward to updating the investor community as we continue to execute on our aggressive growth strategy.